The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 10:56 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #73. Acorda Therapeutics, Inc. Neuronex, Inc.

Acquirer: Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acquiree: Neuronex, Inc.
Details: Acorda Therapeutics, Inc. announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of episodic motor fluctuations, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija utilizes Co.'s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Co. also markets Ampyra (dalfampridine) extended release tablets, 10 mg for improving walking in patients with multiple sclerosis. Ampyra is marketed as Fampyra outside the U.S.

Open the ACOR Page at The Online Investor »

Company Name: 
Acorda Therapeutics Inc
Website: 
www.acorda.com
Sector: 
Biotechnology
Number of ETFs Holding ACOR: 
4
Total Market Value Held by ETFs: 
$148682
Total Market Capitalization: 
$6.00M
% of Market Cap. Held by ETFs: 
2.48%
 

Open the ACOR Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree ACOR Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 73 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.